Literature DB >> 16932923

Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence.

Mohammed Shoaib1.   

Abstract

RATIONALE: The nicotinic receptor agonist, isoarecolone, has 'nicotine-like' subjective properties as detected by rats in a discrimination paradigm. However, isoarecolone lacks the intra-accumbens dopamine-releasing effects, a feature akin to most abused substances. In the five-choice serial reaction time task, isoarecolone can enhance attention and thus may be developed as a cognitive enhancer.
OBJECTIVE: The present experiments assess the dependence profile of isoarecolone in rodent models of nicotine dependence. METHOD AND
RESULTS: Tests for cross-substitution in which isoarecolone is substituted for nicotine [0.3 mg/kg/infusion (inf)] self-administration suggest isoarecolone to have nominal reinforcing properties (0.3 or 1.0 mg/kg/inf); intake of isoarecolone declined over three test sessions in which responding was no different from saline extinction, and behaviour was reinstated by re-presenting nicotine. In a model of nicotine-seeking behaviour, rats having been extinguished by removal of nicotine (0.03 mg/kg/inf) and associated cues, the presentation of priming doses of nicotine (0.1-0.4 mg/kg s.c.) with the cues robustly reinstated responding of nicotine-seeking behaviour. Tests with priming doses of isoarecolone (1-20 mg/kg s.c.) shown previously to generalise to nicotine in discrimination tests produced significant levels of reinstatement but the responses were significantly less compared to nicotine-induced reinstatement.
CONCLUSION: Overall, these results suggest that isoarecolone with its unique profile of behavioural activity should be further examined for treating chronic diseases that are characterised by attentional dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932923     DOI: 10.1007/s00213-006-0498-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  The nicotinic receptor agonists (-)-nicotine and isoarecolone differ in their effects on dopamine release in the nucleus accumbens.

Authors:  N R Mirza; Q Pei; I P Stolerman; T S Zetterström
Journal:  Eur J Pharmacol       Date:  1996-01-11       Impact factor: 4.432

2.  Nicotine reinstatement of nicotine self-administration after long-term extinction.

Authors:  C Chiamulera; C Borgo; S Falchetto; E Valerio; M Tessari
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Persistent behavior at high rates maintained by intravenous self-administration of nicotine.

Authors:  S R Goldberg; R D Spealman; D M Goldberg
Journal:  Science       Date:  1981-10-30       Impact factor: 47.728

4.  Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.

Authors:  Michela Andreoli; Michela Tessari; Maria Pilla; Enzo Valerio; Jim J Hagan; Christian A Heidbreder
Journal:  Neuropsychopharmacology       Date:  2003-04-16       Impact factor: 7.853

5.  Nicotine maintains robust self-administration in rats on a limited-access schedule.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats.

Authors:  C Reavill; C E Spivak; I P Stolerman; J A Waters
Journal:  Neuropharmacology       Date:  1987-07       Impact factor: 5.250

7.  Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Authors:  Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

8.  Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats.

Authors:  P Whiteaker; H S Garcha; S Wonnacott; I P Stolerman
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 9.  The scientific case that nicotine is addictive.

Authors:  I P Stolerman; M J Jarvis
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

10.  Isoarecolone-induced enhancement of delayed matching to sample performance in monkeys: role of nicotinic receptors.

Authors:  J J Buccafusco; W J Jackson; M Gattu; A V Terry
Journal:  Neuroreport       Date:  1995-05-30       Impact factor: 1.837

View more
  9 in total

1.  Attenuating Nicotine Reinforcement and Relapse by Enhancing Endogenous Brain Levels of Kynurenic Acid in Rats and Squirrel Monkeys.

Authors:  Maria E Secci; Alessia Auber; Leigh V Panlilio; Godfrey H Redhi; Eric B Thorndike; Charles W Schindler; Robert Schwarcz; Steven R Goldberg; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-01-31       Impact factor: 7.853

2.  Methamphetamine-like discriminative-stimulus effects of nicotinic agonists.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-03       Impact factor: 4.030

Review 3.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

4.  Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.

Authors:  Sarah L Withey; Michelle R Doyle; Jack Bergman; Rajeev I Desai
Journal:  J Pharmacol Exp Ther       Date:  2018-05-21       Impact factor: 4.030

5.  Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors.

Authors:  Paola Mascia; Marco Pistis; Zuzana Justinova; Leigh V Panlilio; Antonio Luchicchi; Salvatore Lecca; Maria Scherma; Walter Fratta; Paola Fadda; Chanel Barnes; Godfrey H Redhi; Sevil Yasar; Bernard Le Foll; Gianluigi Tanda; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2011-04-01       Impact factor: 13.382

6.  Contextual stimuli modulate extinction and reinstatement in rodents self-administering intravenous nicotine.

Authors:  Victoria C Wing; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2008-06-28       Impact factor: 4.530

7.  Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds.

Authors:  Nicole A Horenstein; Marta Quadri; Clare Stokes; Mohammed Shoaib; Roger L Papke
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

8.  The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.

Authors:  Aliou B Gueye; Yaroslaw Pryslawsky; Jose M Trigo; Nafsika Poulia; Foteini Delis; Katerina Antoniou; Michael Loureiro; Steve R Laviolette; Kiran Vemuri; Alexandros Makriyannis; Bernard Le Foll
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-30       Impact factor: 5.176

Review 9.  The endocannabinoid system: a new molecular target for the treatment of tobacco addiction.

Authors:  Maria Scherma; Paola Fadda; Bernard Le Foll; Benoit Forget; Walter Fratta; Steven R Goldberg; Gianluigi Tanda
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.